BRIEF-U.S. FDA designates Mallinckrodt's StrataGraft as Regenerative Medicine Advanced Therapy
July 18, 2017 at 07:14 AM EDT
* Mallinckrodt- investigational, tissue-based therapy StrataGraft currently under evaluation in a Phase 3 trial Source text for Eikon: Further company coverage:
